Text Size
20 studies found for:    Annexin V

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
Conditions: Antiphospholipid Syndrome;   Thrombophilia Due to Antiphospholipid Antibody;   Systemic Lupus Erythematosus
Intervention: Other: Phlebotomy
2 Unknown † The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance
Conditions: AMPD;   Ischemic Tolerance
Interventions: Drug: systemic administration of 99mTc-HYNIC-Annexin A5;   Behavioral: 10 minutes of ischemic handgripping
3 Withdrawn Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise
Conditions: Cardiovascular Disease;   Ischemia-Reperfusion Injury;   Postconditioning
Intervention: Procedure: repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise
4 Completed The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.
Conditions: Ischemia-Reperfusion Injury;   The Metabolic Syndrome
Intervention: Drug: rosiglitazone
5 Completed Rosuvastatin and Ischemia Reperfusion
Condition: Ischemia
Intervention: Drug: Rosuvastatin
6 Completed The Effect of Caffeine on Ischemic Preconditioning
Conditions: Caffeine;   Ischemic Preconditioning;   Ischemia-Reperfusion Injury
Interventions: Drug: caffeine;   Drug: Technetium-TC99m-labeled Annexin A5;   Procedure: ten minutes forearm ischemia;   Procedure: ischemic forearm exercise
7 Suspended Opioid Receptors Influence Ischemia-Reperfusion Injury
Condition: Ischemia-Reperfusion Injury
Interventions: Drug: morphine;   Drug: naloxone;   Drug: Technetium-TC99m-labeled Annexin A5;   Procedure: forearm ischemic exercise;   Procedure: ten minute forearm ischemia
8 Completed Ischemic Injury and Ischemic Preconditioning in Diabetes
Conditions: Diabetes Mellitus, Insulin-Dependent;   Ischemia-Reperfusion Injury
Interventions: Procedure: Ischemic preconditioning;   Procedure: Forearm ischemic exercise;   Procedure: Annexin A5 scintigraphy;   Drug: Diazoxide;   Drug: glibenclamide;   Drug: adenosine
9 Completed Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?
Conditions: Ischemia Reperfusion Injury;   Cardiovascular Disease
Intervention: Drug: atorvastatin
10 Active, not recruiting Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck
Condition: Head and Neck Cancer
Intervention: Drug: raltegravir and cisplatin
11 Recruiting DCE-MRI PET Bevacizumab Study in Rectal Cancer
Condition: Rectal Cancer Patients
Intervention: Drug: Bevacizumab 5 mg/kg
12 Unknown † Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis
Condition: Endometriosis
Intervention:
13 Recruiting Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Condition: Neoplasms
Intervention: Drug: BAY1000394
14 Completed Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?
Conditions: Cardiovascular Disease;   Ischemia-Reperfusion Injury
Interventions: Drug: Dipyridamole;   Drug: caffeine
15 Completed Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?
Condition: Ischemia Reperfusion Injury
Intervention: Drug: Rosuvastatin
16 Completed Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?
Conditions: Ischemia-Reperfusion Injury;   Atherosclerosis
Intervention: Drug: dipyridamole
17 Unknown † Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model
Conditions: Ischemia-Reperfusion Injury;   Myocardial Infarction
Interventions: Drug: Epoetin alpha;   Drug: NaCl
18 Completed Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury
Conditions: Ischemia Reperfusion Injury;   Endothelial Dysfunction
Interventions: Drug: rosuvastatin;   Drug: atorvastatin 3 days;   Drug: placebo;   Drug: rosuvastatin 7 days;   Drug: atorvastatin 7 days;   Drug: placebo 7 days
19 Active, not recruiting ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling
Conditions: Hypertension;   Left Ventricle Hypertrophy
Interventions: Drug: Aliskiren;   Drug: Losartan
20 Active, not recruiting Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Leukemia;   Prolymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: obatoclax mesylate;   Drug: fludarabine phosphate;   Biological: rituximab;   Other: laboratory biomarker analysis
To Top

† Indicates status has not been verified in more than two years